Article By:
ChinaBio® Today
Sunday, January 5, 2020 10:20 AM EDT
I-Mab, a Phase III Shanghai immunoncology-autoimmune biopharma, announced the terms for its $100 million IPO on the NASDAQ exchange at a market value of $750 million. The company plans to offer 7.4 million shares between $12 and $15.